D. Boral Capital Downgrades Can-Fite BioPharma (CANF) to Hold

D. Boral Capital analyst Jason Kolbert downgraded Can-Fite BioPharma (NYSE: CANF) from Buy to Hold.

The analyst commented: "Can-Fite announced that its Board of Directors approved a reverse split of its ordinary shares alongside a corresponding change in the American Depository Share ratio, following prior shareholder approval. The actions are designed to consolidate the company’s capital structure while maintaining proportional ownership and voting power for existing shareholders. Consistent with our policy we are lowering our rating from Buy to Hold ahead of the actual split."

For an analyst ratings summary and ratings history on Can-Fite BioPharma click here. For more ratings news on Can-Fite BioPharma click here.

Shares of Can-Fite BioPharma closed at $0.24 yesterday.

You May Also Be Interested In

• Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
• Freedom Broker Upgrades Alico Inc. (ALCO) to Buy
• Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37